Peginterferon alfa‐2a for hepatitis C after liver transplantation: Two randomized, controlled trials
Naga Chalasani, Cosme Manzarbeitia, Peter Ferenci, Wolfgang Vogel, Robert J. Fontana, Michael Voigt, Caroline Riely, Paul Martin, Lewis Teperman, James Jiao, Juan Carlos Lopez‐Talavera – 19 January 2005 – There is currently no effective treatment for recurrent hepatitis C after orthotopic liver transplantation (OLT). We therefore performed two randomized, controlled trials—a prophylaxis trial and a treatment trial—to evaluate the safety and efficacy of peginterferon alfa‐2a in patients who had undergone OLT.